NEW YORK, May 22, 2017 /PRNewswire/ --
Stock-Callers.com has initiated reports coverage on four Drug Manufacturers companies, namely: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ: APRI), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). According to an IBISWorld report, over the five years to 2022, investments in research and development that generate a high return will occur, as many pharmaceutical manufacturers will strengthen their drug pipeline with orphan drugs, which typically have a smaller disease population and lower requirements for the number of patients tested during clinical trials. Download the free research reports on these stocks today:
New York headquartered Synergy Pharmaceuticals Inc.'s stock saw a drop of 1.75%, finishing last Friday's trading session at $3.92. A total volume of 3.80 million shares was traded. The Company's shares are trading below their 50-day moving average by 11.44%. Additionally, shares of Synergy Pharma, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have a Relative Strength Index (RSI) of 44.37.
On May 10th, 2017, Synergy Pharmaceuticals reported its financial results and business update for the three months ended March 31st, 2017. The Company had approximately $139.3 million of cash and cash equivalents on hand as of March 31st, 2017. Net cash used in operating activities was $63.5 million, net deferred revenues were $4.3 million, net sales were approximately $0.1 million, and cost of goods sold was approximately $1.8 million during the quarter. See our free and comprehensive research report on SGYP at:
Shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S ended at $40.85, up 1.01% from the last trading session. The stock recorded a trading volume of 1.82 million shares. The Company's shares have advanced 12.23% in the past month, 17.50% over the previous three months, and 16.19% since the start of this year. The stock is trading 12.00% and 8.52% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 66.26.
On May 03rd, 2017, Novo Nordisk announced the availability of its new combination therapy Xultophy®100/3.6 (insulin degludec and liraglutide injection, 100 units/mL and 3.6 mg/mL) at pharmacies nationwide. Xultophy® 100/3.6 combines long-acting basal insulin Tresiba® (insulin degludec U-100) with the #1 prescribed, glucagon-like, peptide-1 receptor-agonist therapy Victoza® (liraglutide)1 in a single, once-daily injection. NVO free research report PDF is just a click away at:
On Friday, shares in San Diego, California headquartered Apricus Biosciences Inc. recorded a trading volume of 213,607 shares. The stock rose 1.98%, closing the day at $1.03. The Company's shares are trading 39.55% below their 50-day moving average. Additionally, shares of Apricus Biosciences, which focuses on the development and commercialization of product candidates in the areas of urology and rheumatology, have an RSI of 34.21.
On April 26th, 2017, research firm Rodman & Renshaw initiated a 'Buy' rating on the Company's stock, with a target price of $4 per share.
On May 04th, 2017, Apricus Biosciences reported that the Vitaros drug-device combination human factor testing study required by the FDA is underway. The Company expects this study to be completed in Q2 2017, and the results will be incorporated into its planned Vitaros NDA re-submission, which remains on track for Q3 2017. Sign up for your complimentary report on APRI at:
At the close of trading on Friday, shares in Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc. recorded a trading volume of 403,056 shares. The stock finished the session 0.96% higher at $10.55. The Company's shares have gained 8.21% in the past month. The stock is trading above its 50-day moving average by 1.65%. Furthermore, shares of Sucampo Pharma, which focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the US, Japan, Switzerland, and internationally, have an RSI of 54.07.
On May 03rd, 2017, Sucampo Pharma reported consolidated financial results for the first quarter ended March 31st, 2017. Total revenues for Q1 2017 were $56.3 million, EBITDA was $18.0 million, GAAP net income was $4.6 million, and diluted EPS was $0.10. At March 31st, 2017, cash, cash equivalents, restricted cash and investments were $243.7 million compared to $198.5 million at December 31st, 2016. Register for free on Stock-Callers.com and download the latest research report on SCMP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA